<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Bennett JM</submitter><funding>Cancer Research UK</funding><funding>Francis Crick Institute</funding><funding>NIAID NIH HHS</funding><funding>The Francis Crick Institute</funding><funding>Medical Research Council</funding><funding>U.S. Department of Defense</funding><funding>National Institutes of Health</funding><funding>Bill and Melinda Gates Foundation</funding><funding>Wellcome Trust</funding><funding>NIGMS NIH HHS</funding><pagination>1714-1728.e10</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11457795</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>31(9)</volume><pubmed_abstract>Malaria, caused by Plasmodium falciparum, remains a significant health burden. One major barrier for developing antimalarial drugs is the ability of the parasite to rapidly generate resistance. We previously demonstrated that salinipostin A (SalA), a natural product, potently kills parasites by inhibiting multiple lipid metabolizing serine hydrolases, a mechanism that results in a low propensity for resistance. Given the difficulty of employing natural products as therapeutic agents, we synthesized a small library of lipidic mixed alkyl/aryl phosphonates as bioisosteres of SalA. Two constitutional isomers exhibited divergent antiparasitic potencies that enabled the identification of therapeutically relevant targets. The active compound kills parasites through a mechanism that is distinct f</pubmed_abstract><journal>Cell chemical biology</journal><pubmed_title>Mixed alkyl/aryl phosphonates identify metabolic serine hydrolases as antimalarial targets.</pubmed_title><pmcid>PMC11457795</pmcid><funding_grant_id>INV-033538</funding_grant_id><funding_grant_id>R33 AH27581</funding_grant_id><funding_grant_id>R01 AI141366</funding_grant_id><funding_grant_id>R01 AI109023</funding_grant_id><funding_grant_id>220318/A/20/Z</funding_grant_id><funding_grant_id>W81XWH2210520</funding_grant_id><funding_grant_id>CC2129</funding_grant_id><funding_grant_id>T32 GM113854</funding_grant_id><funding_grant_id>R01 GM145886</funding_grant_id><funding_grant_id>W81XWII2210520</funding_grant_id><funding_grant_id>R33 AI127581</funding_grant_id><pubmed_authors>Yeo T</pubmed_authors><pubmed_authors>Kabeche S</pubmed_authors><pubmed_authors>Muir R</pubmed_authors><pubmed_authors>Li VL</pubmed_authors><pubmed_authors>Abegg D</pubmed_authors><pubmed_authors>Faucher F</pubmed_authors><pubmed_authors>Fidock DA</pubmed_authors><pubmed_authors>Thathy V</pubmed_authors><pubmed_authors>Bennett JM</pubmed_authors><pubmed_authors>Lovell S</pubmed_authors><pubmed_authors>Adibekian A</pubmed_authors><pubmed_authors>Yeh E</pubmed_authors><pubmed_authors>Bogyo M</pubmed_authors><pubmed_authors>Blackman MJ</pubmed_authors><pubmed_authors>Hackett F</pubmed_authors><pubmed_authors>Narwal SK</pubmed_authors></additional><is_claimable>false</is_claimable><name>Mixed alkyl/aryl phosphonates identify metabolic serine hydrolases as antimalarial targets.</name><description>Malaria, caused by Plasmodium falciparum, remains a significant health burden. One major barrier for developing antimalarial drugs is the ability of the parasite to rapidly generate resistance. We previously demonstrated that salinipostin A (SalA), a natural product, potently kills parasites by inhibiting multiple lipid metabolizing serine hydrolases, a mechanism that results in a low propensity for resistance. Given the difficulty of employing natural products as therapeutic agents, we synthesized a small library of lipidic mixed alkyl/aryl phosphonates as bioisosteres of SalA. Two constitutional isomers exhibited divergent antiparasitic potencies that enabled the identification of therapeutically relevant targets. The active compound kills parasites through a mechanism that is distinct f</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Sep</publication><modification>2026-06-02T09:37:40.324Z</modification><creation>2026-05-26T03:06:26.41Z</creation></dates><accession>S-EPMC11457795</accession><cross_references><pubmed>39137783</pubmed><doi>10.1016/j.chembiol.2024.07.006</doi></cross_references></HashMap>